Syneos Health, Inc. - (SYNH): Price and Financial Metrics

Syneos Health, Inc. - (SYNH): $34.94

0.42 (+1.22%)

POWR Rating

Component Grades














  • SYNH scores best on the Value dimension, with a Value rank ahead of 91.56% of US stocks.
  • SYNH's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • SYNH's current lowest rank is in the Momentum metric (where it is better than 19.86% of US stocks).

SYNH Stock Summary

  • SYNH's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,068.44 -- higher than 98.4% of US-listed equities with positive expected earnings growth.
  • In terms of volatility of its share price, SYNH is more volatile than 86.24% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SYNH comes in at 8.57% -- higher than that of 80.68% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to SYNEOS HEALTH INC, a group of peers worth examining would be FHB, HFBL, EFX, PB, and BERY.
  • Visit SYNH's SEC page to see the company's official filings. To visit the company's web site, go to

SYNH Valuation Summary

  • SYNH's EV/EBIT ratio is 16; this is 142.42% higher than that of the median Healthcare stock.
  • SYNH's price/sales ratio has moved down 0.5 over the prior 102 months.

Below are key valuation metrics over time for SYNH.

Stock Date P/S P/B P/E EV/EBIT
SYNH 2023-03-24 0.7 1 13.4 16.0
SYNH 2023-03-23 0.6 1 12.9 15.7
SYNH 2023-03-22 0.6 1 13.1 15.8
SYNH 2023-03-21 0.7 1 13.6 16.1
SYNH 2023-03-20 0.7 1 13.2 15.9
SYNH 2023-03-17 0.6 1 12.9 15.7

SYNH Growth Metrics

    Its 2 year revenue growth rate is now at 13.14%.
  • Its 5 year net income to common stockholders growth rate is now at 67.37%.
  • Its year over year net income to common stockholders growth rate is now at 22.4%.
Over the past 70 months, SYNH's revenue has gone up $3,813,655,000.

The table below shows SYNH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 5,393.082 426.981 266.497
2022-09-30 5,406.599 489.143 286.928
2022-06-30 5,418.606 405.272 278.122
2022-03-31 5,340.478 394.077 242.283
2021-12-31 5,212.97 450.278 234.831
2021-09-30 4,979.605 378.625 250.758

SYNH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SYNH has a Quality Grade of D, ranking ahead of 21.57% of graded US stocks.
  • SYNH's asset turnover comes in at 0.618 -- ranking 262nd of 563 Business Services stocks.
  • INS, HURN, and MEDP are the stocks whose asset turnover ratios are most correlated with SYNH.

The table below shows SYNH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.618 0.233 0.100
2021-06-30 0.602 0.238 0.096
2021-03-31 0.579 0.234 0.085
2020-12-31 0.580 0.230 0.083
2020-09-30 0.602 0.225 0.067
2020-06-30 0.612 0.218 0.070

SYNH Price Target

For more insight on analysts targets of SYNH, see our SYNH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $80.92 Average Broker Recommendation 1.33 (Strong Buy)

SYNH Stock Price Chart Interactive Chart >

Price chart for SYNH

SYNH Price/Volume Stats

Current price $34.94 52-week high $85.45
Prev. close $34.52 52-week low $22.89
Day low $34.52 Volume 1,083,500
Day high $35.25 Avg. volume 1,745,597
50-day MA $36.53 Dividend yield N/A
200-day MA $48.77 Market Cap 3.61B

Syneos Health, Inc. - (SYNH) Company Bio

Syneos Health, formerly INC Research Holdings, provide the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The company was founded in 2010 and is based in Raleigh, North Carolina.

SYNH Latest News Stream

Event/Time News Detail
Loading, please wait...

SYNH Latest Social Stream

Loading social stream, please wait...

View Full SYNH Social Stream

Latest SYNH News From Around the Web

Below are the latest news stories about SYNEOS HEALTH INC that investors may wish to consider to help them evaluate SYNH as an investment opportunity.

Syneos Health (SYNH) Partners With KX for Data-Driven Insights

Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.

Yahoo | March 23, 2023

Syneos Health and KX Partner to Pioneer Data-Driven Transformation in Biopharmaceutical Asset Development

Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial ExecutionMORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with KX, maker of kdb, the world’s fastest time series database and analytics engine. The partnership will deliver data-driven predictive analytics, Artificial Intelligence (AI) and Machine Learning (ML) capabilities to

Yahoo | March 22, 2023

Syneos Health's (SYNH) New Microsoft Deal to Expand AI Usage

With the multi-year deal, Syneos Health (SYNH) aims to deliver technology and data solutions with Microsoft.

Yahoo | March 21, 2023

Syneos Health inks deal with Microsoft to further use AI

  • Syneos Health (NASDAQ:SYNH) will leverage Microsoft's (NASDAQ:MSFT) Open AI platform to speed up clinical development and improve commercial performance for biopharma customers.
  • Syneos (SYNH) has already developed an advanced analytics platform that utilizes machine...

    Seeking Alpha | March 20, 2023

Syneos Health Collaborates with Microsoft to Accelerate AI Across the Clinical to Commercial Continuum

Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize PerformanceMORRISVILLE, N.C., March 20, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic multi-year agreement with Microsoft. Utilizing Microsoft Azure services, Syneos Health has developed an advanced analytics platform that enables agile deployment of machine learning (ML) supporting the analysis, design and e

Yahoo | March 20, 2023

Read More 'SYNH' Stories Here

SYNH Price Returns

1-mo -7.74%
3-mo -1.27%
6-mo -26.38%
1-year -56.13%
3-year -16.01%
5-year -1.58%
YTD -4.74%
2022 -64.28%
2021 50.71%
2020 14.55%
2019 51.14%
2018 -9.75%

Continue Researching SYNH

Want to see what other sources are saying about Syneos Health Inc's financials and stock price? Try the links below:

Syneos Health Inc (SYNH) Stock Price | Nasdaq
Syneos Health Inc (SYNH) Stock Quote, History and News - Yahoo Finance
Syneos Health Inc (SYNH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8624 seconds.